The regimen of LC has entered an era of precision treatment, so subgroup analysis was conducted in the LC subtypes, and patients were divided into EGFR-mutation and non-EGFR-mutation groups for exploring the potential significance of TNI. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.